Study wrapper · #1263
Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.
Editor's note
A clear-eyed review that resists the pharmacogenomics hype: it notes a large GWAS linking GLP1R variation to weight-loss efficacy and GIPR variants to nausea and vomiting with tirzepatide, then flags those findings as single-cohort, self-reported and unreplicated. Narrative review, no systematic search, so read the predictor list as a research agenda rather than a hierarchy of evidence. The practical takeaway — early on-therapy response is the most defensible individualising signal — is modest and probably right.
Plain-language abstract
A narrative review of why some people respond strongly to GLP-1 and dual GLP-1/GIP drugs while others barely respond at all. Roughly one in ten trial participants with obesity loses less than 5 percent of body weight, and real-world non-response looks more common. The most useful predictor available today is simply how a person responds in the first weeks.